In vitro bactericidal evaluation of a low phase transition temperature liposomal tobramycin formulation as a dry powder preparation against gram negative and gram positive bacteria

Journal of Liposome Research

Volumn 9, Issue 3, 1999, Pages 301-312

  Beaulac, C ^a   Sachetelli, S ^a   Lagace, J ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Aerosolization; Dry powder; Liposomes; Pseudomonas aeruginosa

Indexed keywords

FLUIDOSOME; LIPOSOME; TOBRAMYCIN; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BURKHOLDERIA CEPACIA; DRUG EFFICACY; DRUG FORMULATION; DRY POWDER; ESCHERICHIA COLI; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA;

EID: 0032870133     PISSN: 08982104     EISSN: None     Source Type: Journal    
DOI: 10.3109/08982109909018652     Document Type: Article

References (31)

1. Pederson, S.S., Hoiby, N., Espersen, F., and Koch, C. 1992. Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis. Thorax 47:6-13.
2. Ramphal, R. 1991. The adhesion-receptor systems of Pseudomonas aeruginosa: where are we now? Fifth annual North American cystic fibrosis conference, October 1991. Pediatric and Pulmonology 11 (suppl 6-7):S9.
3. Aronoff, S.C., Quinn, F.J. jr., and Stern, R.C. 1991. Longitudinal serum IgG response to Pseudomonas cepacia surface antigens in cystic fibrosis. Pediatric and Pulmonology. 11:289-93.
4. Thomassen, M.J., Demco, C.A., Klinger, J.D., and Stren, R.C. 1985. Pseudomonas aeruginosa colonization among patients with cystic fibrosis: a new opportunist. American Review of Respiration Diseases. 131:791-796.
5. Tomasz, A. 1994. Multiple-antibiotic resistant pathogenic bacteria. New England Journal of Medecine. 330:1247-1251.
6. Lindsay, C.A., and Bosso, J.A. 1993. Optimization of antibiotic therapy in cystic fibrosis patients. Clinical Pharmacokinetics. 24:496-506.
7. Beaulac, C., Clément-Major, S., Hawari, J, and Lagacé, J. 1997. In vitro kinetics of drug release and pulmonary retention of microencapsulated antibiotics in liposomal formulations in relation to lipid composition. J. Microencapsulation. 14:335-348.
8. Omri, A., Beaulac, C., Bouhajib, M., Montplaisir, S., Sharkawi, M., and Lagacé, J. 1994. Pulmonary retention of free and liposome-encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 38:1090-1095.
9. Beaulac, C., Clément Major, S., Halawari, J., and Lagacé, J. 1996. Eradication of mucoid Pseudomonas aeruginosa with fluid liposome encapsulated tobramycin in an animal model of chronic pulmonary infection. Antimicrobial Agents and Chemotherapy. 40:665-669.
10. Beaulac, C., Sachetelli, S., and Lagacé, J. 1998. In-vitro bactericidal efficacy of sub-MIC concentrations of liposome-encapsulated antibiotic against Gram-negative and Gram-positive bacteria. J. of Antimicrobial Chemother. 41:35-41.
11. Pedersen, S. 1996. Inhalers and nebulizers: which to choose and why. Respiratory medicine 90:67-77.
12. National Comittee for Clinical Laboratory Standards. 1993. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Villanova, Pa.
13. Bartlett, G. 1958. Phosphorus assay in columm chromatography. Clinical and research 234:466-468.
14. Doit, C. P., Bonacorsi, S.P., Fremaux, A.J., Sissia, G., Cohen, R., Geslin, P.L., and Bingen, E.H. 1994. In vitro killing activities of antibiotics at clinically achievable concentrations in cerebrospinal fluid against penicillin-resistant Streotococcus pneumoniae isolated from children with meningitis. Antimicrobial Agents and Chemotherapy. 38:2655-2659.
15. Friedland, I.R., Paris, M., Shelton, S., and McCracken, G.H. 1994. Time-kill studies of antibiotic combinations against penicillin-resistant and -susceptible Streptococcus pneumoniae. J. of Antimicrobial Chemother. 34:231-7.
16. Nikaido, H. 1994. Prevention of drug access to bacterial targets: role of permeability barriers and active efflux. Science 264:382-88.
17. Grinus, L.L., and Goldberg, E.B. 1994. Bacterial multidrug resistance is due to a single membrane protein which functions as a drug pump. J. of Biological Chemistry 269:29998-30004.
18. Ahmed, M., Lyass, L., Markham, P. N., Taylor, S.S., Vazquez-Laslop, N., and Neyfakh A. 1995. Two highly similar multidrug transporters of Bacillus subtilis whose expression is differentially regulated. J. of Bacteriology 177:3904-10.
19. Okusu, H., Ma, D., and Nikaido, H. 1996. AcrAB effux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple resistance (mar) mutants. J. of Bacteriology 178:306-8.
20. Lyon, B.R., and Skurray, R.A. 1987. Antimicrobial resistance of Staphylococcus aureus: genetic basis. [Review] Microbiological Review 51, 88-134.
21. Gilleland L.B., Gilleland H.E., Gibson J.A., and Champlin, F.R. 1989. Adaptive resistance to aminoglycoside antibiotics in Pseudomonas aeruginosa. J. of Medical Microbiology 29:41-50.
22. Gilleland, H.E. 1988. Adaptive alterations in the outer membrane of Gram-negative bacteria during human infections. Canadian Journal of Microbiology 34:499-502.
23. Daikos, G.L., Jackson G.G., Lolans V.T., and Livermore, D.M. 1990. Adaptive resistance to aminoglycoside antibiotics from first-exposure down regulation. J of Infectious Diseases 162:414-20.
24. Daikos, G.L., Lolans, V.T., and Jackson, G.G. 1991. First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use. Antimicrobial Agents and Chemotherapy 35:117-23.
25. Barclay, M.L., Begg E.J., and Chambers, S.T. 1992. Adaptive resistance following single doses of gentamicin in a dynamic in vitro model. Antimicrobial Agents and Chemotherapy 36:1951-57.
26. Barclay, M.L., Begg E.J., Chambers S.T., Thornley P.E., Pattemore P.K., and Grimwood K. 1996. Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis. J of Antimicrobial Chemotherapy 37:1155-64.
27. Mehta, R.T., Keyhani A., McQueen T.J., Rosebaum B., Rolston K.V., and Tarrand J.J. 1993. In-vitro activities of free and liposomal drugs against Mycobacterium avium-M. intracellulare complex and M.tuberculosis. Antimicrobial Agents and Chemotherapy 37:2584-7.
28. Onyeji, C.O., Nightingale C.H., Tessier P.R., Nicolau D.P., Bow L.M. 1995. Activities of clarithromycin, azithromycin, and ofloxacin in combination with liposomal or unencapsulated granulocyte-macrophage colony-stimulating factor against intramacrophage Mycobacterium avium-Mycobacterium intracellulare. J of Infectious Diseases 172:810-6.
29. Beaulac, C. 1995 Elaboration et évaluation de chémoliposomes à action bactéricide anti-Pseudomonas aeruginosa chez un modèle animal d'infection chronique. Master thesis, Université du Québec à Trois-Rivières (UQTR), p 67.
30. Sachetelli, S., Beaulac C., Lagacé J. 1998 Demonstration of a fusion mechanism between a fluid bactericidal liposomal formulation and bacterial cells. Submitted to Biochimica et Biophysica Acta, Biomembranes.
31. Johnson, D.L., Wenger, E.N., and Polikandritou-Lambros, M. 1996. Aerosolization and hygroscopic growth evaluation of lyophilized liposome aerosols under controlled temperature and relative humidity conditions. Aerosol Science and Technology 25:22-30.